Eyestem is a cell therapy company founded by a top-class management team consisting of clinical trial, cell therapy and ophthalmology experts. It also boasts a world class advisory board and we have built collaborations with pioneers and leaders in the space. Our long-term vision is to create a global and scalable cell therapy platform to treat incurable diseases. We are developing a cell therapy platform to produce consistent, quality products over the next few years, concentrating on in vitro efficacy and safety.
We are also establishing processes for manufacturing and controls and instituting GMP manufacturing and GLP studies to cater to market needs worldwide. Our lead product out of the platform is EyecyteRPE aimed at treating Dry AMD (Age-related Macular Degeneration). Dry AMD is the largest cause of incurable blindness in people above 60 and affects roughly 170 million people worldwide. We are currently targeting phase-one trials for EyecyteRPE in the later half of 2020.
Surendran H, Nandakumar S, Konala…
Transplantation of retinal pigment epithelium and photoreceptors generated concomitantly via small molecule-mediated differentiation rescues visual function in rodent models of retinal degeneration
Surendran H, Nandakumar S, Pal…
Human Induced Pluripotent Stem Cell-Derived Lung Epithelial System for SARS-CoV-2 Infection Modeling and Its Potential in Drug Repurposing
Pal R, Surendran H, Nandakumar…
Transplantation of retinal pigment epithelium (RPE) and photoreceptor progenitors (PRP) generated through a xeno-free unified protocol showed improved visual sensitivity in two rodent models
Konala VBR, Nandakumar S, Battu…
Derivation of three induced pluripotent stem cell lines under feeder-free culture conditions from peripheral blood mononuclear cells (PBMC) of Indian patients suffering from inherited retinal diseases carrying different mutations
Project: Hands-on experience in gene editing tools like ZFN, TALEN, CRISPR/Cas9 preferred
Project: Hands-on experience in mammalian cell and tissue culture (preferably with stem or progenitor cells) and basic cell biology techniques